What sets Imunon's technology apart is its rare dual application. The proprietary PlaCCine platform is a non-viral DNA technology being developed to target both infectious diseases and oncology ...

I rate AbbVie stock as a Strong Buy, based on its FDA approval of Rinvoq. Read the latest analysis on the stock here.

I recently received a blast email from a classmate, friend, lawyer, father and former president of the Boston City Council, ...

Oral Presentation Title: Development of a PlaCCine DNA Technology for Safe, Effective and Durable Vaccines Presenting Author: Douglas V. Faller, M.D., Ph.D., Chief Medical Officer, IMUNON Date and ...

Enables accurate analysis of protein complexes, nucleic acids, and gene delivery vehicles, including distinguishing between ...

Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, ...

Then, demand for its COVID-19 vaccine started to diminish. As hospitals resumed normal operations and anti-vaccine sentiment ...

Studies are sounding alarm bells regarding the safety of COVID-19 mRNA vaccines, particularly in light of new findings linking these injections to an increased risk of myocarditis, a potentially fatal ...

Groundbreaking Study Raises Serious Concerns About COVID mRNA Vaccine Safety** A recent peer-reviewed study has emerged that scrutinizes the safety and implications of COVID-19 ...

A team of researchers from Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) and Tsinghua ...

BOSTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Fast Company has named Eascra Biotech, a nanomedicine startup, to its annual Next ...